250 patients in each treatment arm would provide at least 80 % power ( two-tailed alpha of 0.05 ) to demonstrate a reduction in patient-reported non-adherence from 20 % to 10 % in the NMS arm compared with current practice , assuming a 20 % drop-out rate .